Trial · NCT03219333
Results by group252
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 252
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) | Enfortumab Vedotin - Cohort 1 | 44 | 95% Confidence Interval 35.1 to 53.2 | Percentage of Participants | |
| Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) | Enfortumab Vedotin - Cohort 2 | 51.7 | 95% Confidence Interval 40.8 to 62.4 | Percentage of Participants | |
| Duration of Objective Response (DOR) Per BICR | Enfortumab Vedotin - Cohort 1 | 7.6 | 95% Confidence Interval 6.34 to NA | Months | |
| Duration of Objective Response (DOR) Per BICR | Enfortumab Vedotin - Cohort 2 | 10.9 | 95% Confidence Interval 5.78 to NA | Months | |
| Progression-Free Survival (PFS) Per BICR | Enfortumab Vedotin - Cohort 1 | 5.8 | 95% Confidence Interval 4.93 to 7.46 | Months | |
| Progression-Free Survival (PFS) Per BICR | Enfortumab Vedotin - Cohort 2 | 5.8 | 95% Confidence Interval 5.03 to 8.28 | Months | |
| ORR Per Investigator Assessment | Enfortumab Vedotin - Cohort 1 | 39 | 95% Confidence Interval 30.6 to 48.3 | Percentage of Participants | |
| ORR Per Investigator Assessment | Enfortumab Vedotin - Cohort 2 | 50.6 | 95% Confidence Interval 39.8 to 61.3 | Percentage of Participants | |
| DOR Per Investigator Assessment | Enfortumab Vedotin - Cohort 1 | 7.9 | 95% Confidence Interval 5.95 to NA | Months | |
| DOR Per Investigator Assessment | Enfortumab Vedotin - Cohort 2 | 10.7 | 95% Confidence Interval 5.85 to 16.59 | Months | |
| PFS Per Investigator Assessment | Enfortumab Vedotin - Cohort 1 | 5.8 | 95% Confidence Interval 4.93 to 7.46 | Months | |
| PFS Per Investigator Assessment | Enfortumab Vedotin - Cohort 2 | 7.2 | 95% Confidence Interval 5.42 to 7.69 | Months | |
| Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology) | Enfortumab Vedotin - Cohort 1 | Hemoglobin decreased (all grades) | 52 | Participants | |
| Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology) | Enfortumab Vedotin - Cohort 2 | Hemoglobin decreased (all grades) | 39 | Participants | |
| Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology) | Enfortumab Vedotin - Cohort 1 | Hemoglobin decreased (grade 3-4) | 12 | Participants | |
| Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology) | Enfortumab Vedotin - Cohort 2 | Hemoglobin decreased (grade 3-4) | 4 | Participants | |
| Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology) | Enfortumab Vedotin - Cohort 1 | Leukocytes decreased (all grades) | 33 | Participants | |
| Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology) | Enfortumab Vedotin - Cohort 2 | Leukocytes decreased (all grades) | 28 | Participants | |
| Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology) | Enfortumab Vedotin - Cohort 1 | Leukocytes decreased (grade 3-4) | 5 | Participants | |
| Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology) | Enfortumab Vedotin - Cohort 2 | Leukocytes decreased (grade 3-4) | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03219333/results